LIOTHYRONINE SODIUM

Post-LOE

liothyronine sodium

Biocon

ANDAORALTABLET

Approved

Nov 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LIOTHYRONINE SODIUM (liothyronine sodium) by Biocon is synthesis. Approved for hypothyroidism during the recovery phase of subacute thyroiditis. First approved in 2012.

Drug data last refreshed 19h ago

Mechanism of Action

synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…

Indications (1)

hypothyroidism during the recovery phase of subacute thyroiditis

Company

Worked on LIOTHYRONINE SODIUM at Biocon? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.